Escient is a clinical-stage pharmaceutical company focused on discovering and developing first-in-class therapies to address serious, unserved medical needs. The company is led by an experienced team with specific expertise in GPCR drug discovery and development. Escient's pipeline consists of a novel antagonist targeting MrgprX2 for the treatment of chronic urticaria and atopic dermatitis as well as a novel antagonist targeting MrgprX4 for the treatment of cholestatic pruritis. In June 2024 Escient was acquired by Incyte (Nasdaq: INCY)